Based on KFF analysis of Medicare data from 2020, an estimated 7% of Medicare beneficiaries, or 3.6 million overall, had established cardiovascular disease and obesity or overweight in 2020, and so could be eligible for Medicare coverage of Wegovy for its new indication (Figure 1) (see Methods for details)
Pharmacokinetics The time course of drug absorption, distribution, metabolism and excretion
Yes, switching from Zepbound ( tirzepatide ) to Wegovy ( semaglutide ) is possible, as long as your healthcare provider thinks it's the right move for you
Beyond MASLD, emerging preclinical evidence highlights the therapeutic potential of GLP-1 RAs in ALD and MetALD (Singal and Leggio, 2025)
Tirzepatide is a dual GLP-1RA and glucose-dependent insulinotropic polypeptide receptor agonist, exerting synergistic effects on insulin secretion and weight reduction [4], and offering enhanced efficacy compared to semaglutide
Cch s dng thuc GLP-1 Hin ti c ba thuc ng vn th th GLP-1 c FDA Hoa K chp thun kim sot cn nng l Saxenda (liraglutide), Wegovy (semaglutide) v Zepbound (tirzepatide): Saxenda (liraglutide): Saxenda c FDA Hoa K ph duyt t thng 12/2014 kim sot cn nng ngi ln
